PAR-2 Antibody Blocking for Broad Receptor Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for potent antibodies that can broadly antagonize the activation of human Protease-Activated Receptor-2 (PAR-2) to treat diseases associated with its overexpression, such as asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, cancer, skin diseases, and inflammatory conditions, as existing treatments are inadequate.
Innovation Solution
Development of isolated antibodies and antigen-binding fragments that specifically bind to human PAR-2, inhibiting its activation by PAR-2 activating ligands, including those that do not interact with the N-terminus of PAR-2, with varying IC50 values and efficacy in blocking activation and calcium flux, and are suitable for human administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used, then treatment options are available, but they are inadequate for effectively treating diseases associated with PAR-2 overexpression
Solution Approach 1:
The patent develops a monoclonal antibody (anti-PAR-2) that can treat multiple different diseases (asthma, COPD, pulmonary fibrosis, cancer, skin diseases, inflammatory conditions) by targeting a common receptor (PAR-2) that is overexpressed across these diverse conditions. This single antibody serves multiple therapeutic functions, resolving the contradiction between treatment effectiveness and adaptability to various diseases.
Solution Approach 2:
The patent modifies the antibody's binding characteristics by selecting and characterizing antibodies with specific IC50 values (ranging from 0.1 nM to 17 nM) to optimize their antagonistic activity against PAR-2 activation. This parameter optimization ensures high reliability of treatment effectiveness across different disease models while maintaining versatility.
2Reliability
If antibodies bind to the N-terminus of PAR-2, then activation is blocked, but the scope of blocking is limited
Solution Approach 1:
The patent identifies and targets a specific epitope on the extracellular domain of PAR-2 that is distinct from the N-terminus binding site. By segmenting the binding site selection, the antibody achieves broad blocking of PAR-2 activation without being constrained to a single binding location, thereby improving both reliability of activation blocking and adaptability to different PAR-2 conformations and disease states.
Solution Approach 2:
The antibody acts as an intermediary that blocks the interaction between PAR-2 activating ligands and the receptor. By binding to a specific epitope on the extracellular domain, the antibody prevents ligand-receptor interaction without requiring direct binding to the N-terminus, thus achieving reliable activation blocking with enhanced binding specificity and adaptability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively inhibit PAR-2 activation, reducing associated diseases by at least 70-98% in various models, demonstrating therapeutic potential for airway diseases, pain relief, skin diseases, cancer, and inflammatory conditions.
Implementation Method 1
an isolated antibody or antigen-binding fragment that specifically binds to human PAR-2
Implementation Method 2
which antagonizes activation of PAR-2 by a PAR-2 activating ligand
Implementation Method 3
inhibits activation of human PAR-2 by a soluble PAR-2 activating ligand with an IC50 from about 0.1 nM to about 17 nM
Data Source
AI summary
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PAR-2 and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PAR-2 block the interaction between a PAR-2 activating ligand and an extracellular domain of PAR-2, and/or blocks PAR-2 activation by a PAR-2 activating ligand, In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased expression of PAR-2 and/or diseases or conditions that can be alleviated by antagonizing activation of PAR-2 by a PAR-2 activating ligand (e.g., airway diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).